Cross-reactive antibody responses to coronaviruses elicited by
SARS-CoV-2 infection or vaccination
Richard SH Lee1, Samuel MS Cheng1,
Jin Zhao1, Annie YS Tsoi1, Kaman KM
Lau1, CoCo HC Chan1, John KC
Li1, David SC Hui2, Malik
Peiris1,3*, Hui-Ling Yen1*
1School of Public Health, LKS Faculty of Medicine, The
University of Hong Kong
2Department of Medicine and Therapeutics, CUHK, Prince
of Wales Hospital, HKSAR, China
3Centre for Immunology & Infection, Hong Kong Science
Park, Hong Kong, China
Running title: SARS-CoV-2 and cross-reactive antibodies
Key words: SARS-CoV-2, human coronaviruses, cross-reactive antibody,
COVID-19 vaccines, convalescent sera
Word count: 214 words (abstract), 2211 words (text); Figures: 3;
References: 22.
Notes:
- The authors declare no conflict of interest.
- Data is available upon request from the corresponding author.
- This study was supported by the HKU URC Seed Funding for Strategic
Interdisciplinary Research Scheme 2021/22, Contract (U01AI151810) of
NIAID, National Institutes of Health, USA, and the Theme-based
Research Scheme (#T11-705/21-N) of the Research Grants Council of the
Hong Kong SAR Government, China.
- The study was approved by the institutional review board of the Hong
Kong West Cluster of the Hospital Authority of Hong Kong (Reference
No.: UW20-169) and the Joint Chinese University of Hong Kong-New
Territories East Cluster Clinical Research Ethics Committee (Reference
No.: 2020.229).
- Correspondence: Hui-Ling Yen
(hyen@hku.hk) and Malik Peiris
(malik@hku.hk).